TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04494139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Canteen intervention
Description: Behavioral intervention: 16 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canteen
Description: Canteen changes to introduce health foods

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canteen
Description: Canteen changes to introduce health foods
Study: NCT01480921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Description: Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:~* 5-10 min warm-up~* 30 min aerobic interval training (walking or stationary bicycle)~* 10 min cool-down~Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised hospital-based exercise training
Description: Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:~* 5-10 min of warm-up~* 30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers~* 10 min of cool down~Exercise will be tracked by the participant in exercise log books.
Study: NCT01968850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate/vitamin D
Description: once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate/vitamin D
Description: once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
Study: NCT01419782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Description: Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
Study: NCT04198454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandages
Description: Class I (20-30 mmHg) compression bandages or stocking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression bandages
Description: Class I (20-30 mmHg) compression bandages or stocking

Intervention type: OTHER
Group type: OTHER
Intervention: Standard wound dressings
Description: Wound dressings alone consisting of gauze and skin tape to cover the wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional ablative carbon dioxide laser
Description: Participant will have laser applied to their wound bed.
Study: NCT02131909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: During a session, the child performs a series of 10 single, bilateral and synchronous movements while viewing the reflected image

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bimanual rehabilitation exercises
Description: During a session, the child performs a series of 10 single, bilateral and synchronous movements while watching his two hands
Study: NCT00750971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
Description: Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
Study: NCT01591525

Intervention type: BEHAVIORAL
Intervention: Education on Type II Diabetes
Description: one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.

Intervention type: BEHAVIORAL
Intervention: Education on Type II Diabetes
Description: one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.

Intervention type: BEHAVIORAL
Intervention: Education on regular visits to a Primary Care Provider
Description: one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.

Intervention type: BEHAVIORAL
Intervention: Education on regular visits to a Primary Care Provider
Description: one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
Study: NCT00750971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
Description: Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
Study: NCT00702325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide / formoterol fumarate (SYMBICORT)
Description: 160/4.5 μg x 2 actuations twice daily (bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
Study: NCT03535714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MANTR-a treatment
Description: MANTR-a treatment
Study: NCT00972426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
Description: Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
Description: Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
Study: NCT01507779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU
Description: IVACFLU is a whole virus vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge Alfpa Wassmann and inactivated with formaldehyde. It was formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose and filled in single dose vials.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
Study: NCT01318252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-54478 0.005%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-54478 Vehicle
Description: Inactive ingredients used as a placebo comparator
Study: NCT04012879

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD19 CART
Description: CD19 CART
Study: NCT03368950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Course
Description: An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Mindfulness Course
Description: An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
Study: NCT01727765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H\&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: inspiratory muscle training
Description: Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H\&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
Study: NCT02556125

Intervention type: DEVICE
Intervention: Diaphragm pacing
Description: Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
Study: NCT02361944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen - normoxia
Description: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen - hyperoxia
Description: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Study: NCT03742635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Movements Assessment
Description: Prechtl's Assessment of General Movements (GMA) is a tool used in early infancy to identify infants at high risk of cerebral palsy and neurodevelopmental impairment. General movements are complex motor patterns that involve the entire body, moving fluidly in different directions through the arms, legs, and trunk with variable speed, amplitude, force and intensity. During fetal development, spontaneously generated motor patterns, including general movements, can already be observed. The GMA is a functional assessment of the maturing nervous system that takes advantage of the fact that typically developing infants will have a progression in their general movements. This pattern is characterized by a writhing pattern in the early weeks post-term, followed by the emergence of fidgety movements at 3-5 months of age.
Study: NCT04029181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-CD8 PET imaging agent
Description: An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-CD8 PET imaging agent
Description: An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8
Study: NCT02910960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquire EUS Biopsy Device
Description: At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SharkCore Biopsy System
Description: At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
Study: NCT00051285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoximone
Description: Participants receive oral enoximone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoximone placebo
Description: Participants receive placebo to match enoximone
Study: NCT01982721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locking mechanism for prosthetic knee
Study: NCT02053324

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AvidinOX/ST2210
Description: One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
Study: NCT01826851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group.
Study: NCT03482687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Me & You: Building Healthy Relationships
Description: Me \& You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game...Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).
Study: NCT03300167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Liquid Biopsy System
Description: The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
Study: NCT02379767

Intervention type: DEVICE
Intervention: Electroconvulsive therapy

Intervention type: OTHER
Intervention: Positron emission tomography of the brain using [11C]harmine

Intervention type: OTHER
Intervention: Positron emission tomography of the brain using [11C]harmine

Intervention type: OTHER
Intervention: Structural magnetic resonance imaging

Intervention type: OTHER
Intervention: Structural magnetic resonance imaging
Study: NCT05132270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea and thalidomide
Description: Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
Study: NCT04475900

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)
Description: To measure corneal biomechanics with Scheimpflug based tonometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)
Description: To measure corneal biomechanics with Scheimpflug based tonometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)
Description: To measure corneal biomechanics with Scheimpflug based tonometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)
Description: To measure corneal topography and tomography with Scheimpflug tomograph

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)
Description: To measure corneal topography and tomography with Scheimpflug tomograph

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)
Description: To measure corneal topography and tomography with Scheimpflug tomograph

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic nerve head measurement
Description: To measure optic nerve excavation

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic nerve head measurement
Description: To measure optic nerve excavation
Study: NCT03960073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: 4 week 20mg oral daily dose of Mito Q

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 week oral daily dose of TTP placebo
Study: NCT01701999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBV A/B
Description: rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
Study: NCT00058474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m2 oral daily 5 days a week on days of planned RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m2 oral daily 5 days a week on days of planned RT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 225 mg/m2 IV daily continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 225 mg/m2 IV daily continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 50 mg/m2 IV 5 days a week on days of planned RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 50 mg/m2 IV 5 days a week on days of planned RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given 5 days a week for 5-6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 5-6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 5-6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 5-6 weeks
Study: NCT02729740

Intervention type: DEVICE
Group type: OTHER
Intervention: Penumbra Smart Coil

Intervention type: DEVICE
Group type: OTHER
Intervention: Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)
Description: Other Penumbra Coils available as standard of care
Study: NCT06424951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LKCM(Loving-kindness and Compassion Meditations)
Description: Loving-kindness and Compassion Meditations
Study: NCT01961401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Study: NCT00882310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
Study: NCT04077541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet platform
Description: The trauma care bundles combined with the internet platform.
Study: NCT00537498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase
Description: Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is \> 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is \< 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is \< 1,6g/l treatment must be stopped and continued after rising up to \>2g/l
Study: NCT02654366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction Group
Description: The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.~The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support.
Study: NCT03032406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus
Study: NCT00698932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg, oral tablet, once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, once daily for 24 weeks
Study: NCT02756351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytaCoat Nasal Prong

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiration Healthcare Inspire nCPAP Nasal Prong
Study: NCT04263012

Intervention type: OTHER
Intervention: collection of patient data
Description: assess mortality rate, rehospitalization and survival rate of patients after receiving an artificial heart implant
Study: NCT01653964

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular breast imaging
Description: Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)